Publications by authors named "Meredith Faggen"

Claim this Profile
V
Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized Study.
Katherine A Schneider, Lauren Massingham, Michelle Weitz, Chanika Phornphutkul, Melissa Leach, Meredith Faggen

JCO Oncol Pract· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial.
Anna Weiss, Qingchun Jin, Nabihah Tayob, Eileen Wrabel, Michelle DeMeo, Meredith Faggen

Ann Surg Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Meredith Faggen

JCO Oncol Pract· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.
Gregory A Abel, Haesook T Kim, Ira Zackon, Edwin T Alyea, Alexandra S Bailey, Meredith A Faggen

JAMA Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley, Meredith Faggen

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Meredith Faggen

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
Christina Mayerhofer, Mina S Sedrak, Judith O Hopkins, Tianyu Li, Nabihah Tayob, Meredith G Faggen

J Natl Cancer Inst· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
Anna Weiss, Tianyu Li, Neelam V Desai, Nadine M Tung, Philip D Poorvu, Meredith Faggen

J Am Coll Surg· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.
Rachel A Freedman, Tianyu Li, Mina S Sedrak, Judith O Hopkins, Nabihah Tayob, Meredith G Faggen

J Geriatr Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors.
Rachel A Freedman, Anna C Revette, Haley Gagnon, Adriana Perilla-Glen, Molly Kokoski, Meredith Faggen

Breast Cancer Res Treat· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer awareness among Afghan refugee women in Turkey.
Mehmet Celal Kizilkaya, Sarah Sabrine Kilic, Mehmet Abdussamet Bozkurt, Osman Sibic, Nisha Ohri, Meredith Faggen

EClinicalMedicine· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.
Adrienne G Waks, Neelam V Desai, Tianyu Li, Philip D Poorvu, Ann H Partridge, Meredith Faggen

NPJ Breast Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B Yurgelun, Douglas A Rubinson, Deborah Schrag, Meredith Faggen

Oncologist· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Meredith Faggen

NPJ Breast Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.
Romualdo Barroso-Sousa, Ines Vaz-Luis, Antonio Di Meglio, Jiani Hu, Tianyu Li, Meredith Faggen

Oncologist· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T Dang, Meredith G Faggen

Breast Cancer Res Treat· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Sara M Tolaney, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Meredith Faggen

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Otto Metzger Filho, Anita Giobbie-Hurder, Nancy U Lin, Meredith Faggen, Steven Come

Breast Cancer Res Treat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of High-Dose vs Standard-Dose Vitamin D Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial.
Justin C Brown, Michael H Rosenthal, Chao Ma, Sui Zhang, Halla S Nimeiri, Meredith A Faggen

Cancers (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study.
Ines Vaz-Luis, Romualdo Barroso-Sousa, Antonio Di Meglio, Jiani Hu, Rebecca Rees, Meredith Faggen

J Clin Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.
Kimmie Ng, Halla S Nimeiri, Nadine J McCleary, Thomas A Abrams, Matthew B Yurgelun, Meredith A Faggen

JAMA· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis